Aprea heading for Phase III with €50M series C round

Aprea Therapeutics AB (Solna, Sweden) raised €50 million ($56.9 million) in a series C round on Nov. 30, with which it intends to fund a Phase III study of lead candidate APR-246 to treat myelodysplastic syndrome (MDS). The small molecule quinuclidinone is designed to promote correct

Read the full 462 word article

User Sign In